| Name | Title | Contact Details |
|---|
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need.
Aurora Biomed is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VelosBio, Inc. operates as a biotechnology firm specializing in oncology.
A next-generation protein therapeutics company pioneering an in vivo biologics design platform. By redesigning in vivo measurement to be available from day one, Manifold Bio has an advantage in solving complex biologic challenges.